Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pudexacianinium - Astellas Pharma

Next Previous
X
Search
Drug Profile

Pudexacianinium - Astellas Pharma

Alternative Names: ASP-5354; ASP5354-chloride; Pudexacianinium chloride - Astellas Pharma

Latest Information Update: 28 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mie University; Nagoya University
  • Developer Astellas Pharma
  • Class Diagnostic agents; Imaging agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Unspecified
  • Phase II Breast cancer; Malignant melanoma

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for phase-I development in Unspecified(In volunteers, In adults) in Japan (IV, Injection)
  • 28 Feb 2024 Astellas Pharma initiates enrolment in a phase-III trial in Unspecified (Diagnosis) in USA (IV) (NCT05999747)
  • 15 Dec 2023 Astellas Pharma terminates a phase II trial in Malignant melanoma (Diagnosis) in USA (Intratumoural) due to the company's strategic decision (NCT05457842)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top